You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Claims for Patent: 8,334,279

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,334,279

Title:	Non-hormonal steroid modulators of NF-κB for treatment of disease
Abstract:	The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
Inventor(s):	John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
Assignee:	Validus Genetics, Reveragen Biopharma Inc
Application Number:	US13/327,628
Patent Claims:	1. A method of treating or reducing the symptoms of muscular dystrophy, comprising the administration, to a patient in need thereof, of a therapeutically effective amount of a compound having the structural formula: 2. The method as recited in claim 1, wherein said muscular dystrophy is selected from the group consisting of Duchenne muscular dystrophy, Becker muscular dystrophy, limb girdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and Emery-Dreifuss muscular dystrophy. 3. The method as recited in claim 2, wherein said muscular dystrophy is Duchenne muscular dystrophy. 4. The method as recited in claim 2, wherein said muscular dystrophy is Becker muscular dystrophy. 5. The method as recited in claim 2, wherein said muscular dystrophy is limb girdle muscular dystrophy. 6. The method as recited in claim 2, wherein said muscular dystrophy is congenital muscular dystrophy. 7. The method as recited in claim 2, wherein said muscular dystrophy is facioscapulohumeral muscular dystrophy. 8. The method as recited in claim 2, wherein said muscular dystrophy is myotonic muscular dystrophy. 9. The method as recited in claim 2, wherein said muscular dystrophy is oculopharyngeal muscular dystrophy. 10. The method as recited in claim 2, wherein said muscular dystrophy is distal muscular dystrophy. 11. The method as recited in claim 2, wherein said muscular dystrophy is Emery-Dreifuss muscular dystrophy.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.